Abstract:Leprosy is a chronic disease of the skin and peripheral nerves caused by Mycobacterium leprae . A major public health and clinical problem are leprosy reactions, which are inflammatory episodes that often contribute to nerve damage and disability. Type I reversal reactions (T1R) can occur after microbiological cure of leprosy and affect up to 50% of leprosy patients. Early intervention to prevent T1R and, hence, nerve damage, is a major focus of current leprosy control efforts. In a prospective study, we enrolled and collected samples from 32 leprosy patients before the onset of T1R. Whole blood aliquots were challenged with M . leprae sonicate or media and total RNA was extracted. After a three-year follow-up, the transcriptomic response was compared between cells from 22 patients who remained T1R-free and 10 patients who developed T1R during that period. Our analysis focused on differential transcript (i.e. isoform) expression and usage. Results showed that, at baseline, cells from T1R-destined and T1R-free subjects had no main difference in their transcripts expression and usage. However, the cells of T1R patients displayed a transcriptomic immune response to M . leprae antigens that was significantly different from the one of cells from leprosy patients who remained T1R-free. Transcripts with significantly higher upregulation in the T1R-destined group, compared to the cells from T1R-free patients, were enriched for pathways and GO terms involved in response to intracellular pathogens, apoptosis regulation and inflammatory processes. Similarly, transcript usage analysis pinpointed different transcript proportions in response to the in-vitro challenge of cells from T1R-destined patients. Hence, transcript usage in concert with transcript expression suggested a dysregulated inflammatory response including increased apoptosis regulation in the peripheral blood cells of T1R-destined patients before the onset of T1R symptoms. Combined, these results provided detailed insight into the pathogenesis of T1R. The prevention and clinical management of type 1 reactions (T1R) remain an important unmet need to reduce nerve damage in leprosy patients. It is not known why 30–50% of leprosy patients will develop T1R. This knowledge gap underlies the need for a better mechanistic understanding of T1R that could lead to biomarker candidates to identify leprosy patients who are at high risk of developing T1R. Here, we used a prospective design in which leprosy patients were enrolled before the onset of T1R.Whole blood samples were obtained at enrollment, aliquots were left unstimulated or were stimulated M . leprae antigens and total RNA was extracted. Patients were followed for three years at which time 10 out of 32 participants had developed T1R. Subsequent transcript expression and usage analyses revealed that groups differed little in their isoform landscape at baseline. Following stimulation, transcriptomic response differences became pronounced. Transcripts with higher response in T1R group preferentially involved genes of intracellular defense and inflammatory pathways. Among these transcripts, non-coding ones had higher frequency in T1R. Our study provided new insights into the T1R pathogenesis by suggesting a role for non-coding transcripts into the immune dysregulations of T1R and providing additional candidate genes and their isoforms to be further investigated.

Interleukin-10 Producing Regulatory B Cells Transformed CD4+CD25− Into Tregs and Enhanced Regulatory T Cells Function in Human Leprosy

Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy

Fate of T cells and their secretary proteins during the progression of leprosy.

The expression of Th17/Treg cells in skin lesions during leprosy, and its clinical significance

CD39+ Regulatory T Cells Suppress Generation and Differentiation of Th17 Cells in Human Malignant Pleural Effusion Via a LAP-dependent Mechanism

Transcriptome immune-regulatory differences between leprosy patients and type 1 reaction patients, before onset of symptoms

Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10

OP0043 the Number of Circulating Regulatory T Cells is Reduced and Low-Dose Il-2 Selectively Stimulates Its Proliferation in Patients with Systemic Lupus Erythematosus

The immune-suppressive landscape in lepromatous leprosy revealed by single-cell RNA sequencing

Tumor Necrosis Factor Suppresses Interleukin 10 in Peripheral B Cells Via Upregulating Bcl2-like Protein 12 in Patients with Inflammatory Bowel Disease.

MicroRNAs correlate with bacillary index and genes associated to cell death processes in leprosy

Identification of a systemic interferon-γ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction

Different profiles of chemokines, cytokines and cell growth factors in plasma samples from patients with leprosy, leprosy reactions and households contacts

Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction

Transcriptomic Analysis of Mycobacterium leprae-Stimulated Response in Peripheral Blood Mononuclear Cells Reveal Potential Biomarkers for Early Diagnosis of Leprosy

IL-10-producing B Cells Regulate Th1/Th17-cell Immune Responses in Pneumocystis Pneumonia.

Immunomodulation of Human CD19+CD25high Regulatory B Cells Via Th17/Foxp3 Regulatory T Cells and Th1/Th2 Cytokines.

CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection

Ablation of B cell-derived IL-10 increases tuberculosis resistance

The modulation of B cells survival and secretion of antibodies by interleukin-17-producing T cells in patients with systemic lupus erythematosus

Innate Immune Responses in Leprosy